PubMed · 7958725
A new beta-adrenoceptor blocking agent derived from dehydrozingerone.
Abstract
1. Dehydrozingeronolol (DZPN; 0.1, 0.5, 1.0 mg/kg, i.v.) produced a dose-dependent bradycardia response and a sustained pressor action in urethane-anesthetized normotensive rats. DZPN inhibited the tachycardia effects by (-)isoproterenol, but had no blocking effect on the arterial pressor responses induced by phenylephrine. 2. In in vitro study, DZPN antagonized (-)isoproterenol-induced positive chronotropic effects in guinea-pig isolated right atria and relaxation responses in rat isolated uterus horns. 3. DZPN causes mild direct cardiac depression at high concentrations without intrinsic sympathomimetic activity (ISA). 4. The order of potency of beta-adrenoceptor antagonists in competing for the [3H]dihydroalprenolol binding sites was (-)propranolol >> DZPN > or = atenolol.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
B N Wu, C R Yang, J M Yang, I J Chen. 1994. A new beta-adrenoceptor blocking agent derived from dehydrozingerone.. https://doi.org/10.1016/0306-3623(94)90242-9
Cite the original work for its findings. Save a collection to share your selection of sources.